<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Neurodegenerative immunotherapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/neurodegenerative-immunotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 09:16:56 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Neurodegenerative immunotherapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Brain-Delivered Antibody Targets Alpha-Synuclein Aggregates</title>
		<link>https://bioengineer.org/brain-delivered-antibody-targets-alpha-synuclein-aggregates/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 23 Aug 2025 13:36:48 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Alpha-synuclein aggregates]]></category>
		<category><![CDATA[Blood-brain barrier delivery]]></category>
		<category><![CDATA[Brain shuttle antibodies]]></category>
		<category><![CDATA[Neurodegenerative immunotherapy]]></category>
		<category><![CDATA[Parkinson’s disease treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/brain-delivered-antibody-targets-alpha-synuclein-aggregates/</guid>

					<description><![CDATA[In a groundbreaking advancement poised to revolutionize the treatment of neurodegenerative disorders, researchers have unveiled a novel brain-shuttled antibody designed specifically to target alpha-synuclein aggregates—a pathological hallmark of synucleinopathies such as Parkinson’s disease. The study, spearheaded by An, McInnis, Kim, and colleagues, provides compelling evidence supporting a therapeutic approach that could potentially mitigate or even [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">257161</post-id>	</item>
	</channel>
</rss>
